MANNKIND CORP Other Non-Current Liabilities
MANNKIND CORP (MNKD) had Other Non-Current Liabilities of $7.05 million as of 2022-03-31, per its 10-Q filed 2022-05-05.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OtherLiabilitiesNoncurrent · last filed 2023-02-23
- 2022-03-31: Other Liabilities, Noncurrent $7.05M.
- 2021-12-31: Other Liabilities, Noncurrent $4.95M.
- 2021-09-30: Other Liabilities, Noncurrent $5.01M.
- 2021-06-30: Other Liabilities, Noncurrent $5.32M.
| Period end | Other Liabilities, Noncurrent | Other Liabilities, Noncurrent as first filed |
|---|---|---|
| 2022-03-31 | $7.05M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $4.95M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $5.01M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $5.32M 10-Q · filed 2021-08-11 | |
| 2016-09-30 | $17.40M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $16.67M 10-Q/A · filed 2016-08-10 | |
| 2016-03-31 | $15.95M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $15.22M 10-Q · filed 2016-11-09 | |
| 2015-09-30 | $14.49M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $12.12M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $26.78M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $12.30M 10-K · filed 2016-03-15 | $15.34M 10-K · filed 2015-03-02 |
| 2014-09-30 | $11.57M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $15.04M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $14.32M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $13.61M 10-K · filed 2015-03-02 | |
| 2013-09-30 | $20.31M 10-Q · filed 2013-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |